CRISPR-Based Diagnostics Market Report 2026

CRISPR-Based Diagnostics Market Overview

• CRISPR-Based Diagnostics market size has reached to $5.1 billion in 2025 • Expected to grow to $11.45 billion in 2030 at a compound annual growth rate (CAGR) of 17.5% • Growth Driver: Rising Incidence Of Infectious Diseases Fuels Growth Of The Market • Market Trend: Strategic Partnership Enhances Accessibility And Global Distribution Of CRISPR Diagnostics • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under CRISPR-Based Diagnostics Market?

CRISPR (clustered regularly interspaced short palindromic repeats)-based diagnostics refers to advanced molecular tools leveraging the CRISPR-Cas system to detect specific nucleic acid sequences with high precision and speed for identifying diseases or genetic markers, offering revolutionary capabilities in medical and genomic analysis. These diagnostics are utilized in applications such as detecting infectious diseases, identifying genetic disorders, and monitoring mutations in cancer research and treatment, with growing potential in personalized medicine and point-of-care testing. The main products of CRISPR-based diagnostics are kits, buffer solutions, software, and others. Kits for CRISPR-based diagnostics are ready-to-use tools designed for rapid, accurate detection of specific genetic material using CRISPR technology, often applied in disease diagnosis and research. The techniques used in this are recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), and others. It is used in diseases such as infectious diseases as well as non-infectious diseases and are utilized by hospitals, diagnostic centers, biotechnology companies, academic and research institutions, among others.

What Is The CRISPR-Based Diagnostics Market Growth Forecast?

The crispr-based diagnostics market size is expected to see rapid growth in the next few years. It will grow to $11.45 billion in 2030 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to growth of decentralized testing models, rising demand for early disease detection, expansion of point-of-care diagnostics, integration with digital health platforms, increasing adoption in oncology and genetic screening. Major trends in the forecast period include rising adoption of rapid molecular diagnostics, expansion of point-of-care testing solutions, increased use in infectious disease detection, integration with isothermal amplification techniques, growth of personalized diagnostic applications.

Global CRISPR-Based Diagnostics Market Segmentation

1) By Product: Kits, Buffer Solutions, Software, Other Products 2) By Technique: Recombinase Polymerase Amplification (RPA), Loop-Mediated Isothermal Amplification (LAMP), Other Techniques 3) By Disease: Infectious Diseases, Non-Infectious Diseases 4) By End-User: Hospitals, Diagnostic Centers, Biotechnology Companies, Academic And Research Institutes, Other End-Users Subsegments: 1) By Kits: CRISPR Detection Kits, CRISPR Amplification Kits, CRISPR-Based Assay Kits 2) By Buffer Solutions: CRISPR Reaction Buffers, CRISPR Lysis Buffers 3) By Software: CRISPR Data Analysis Software, CRISPR Design Software, CRISPR Diagnostic Platforms Software 4) By Other Products: CRISPR Enzymes, CRISPR Reagents, CRISPR-Based Probes

What Is The Driver Of The CRISPR-Based Diagnostics Market?

The rising incidence of infectious diseases is expected to propel the growth of the CRISPR-based diagnostics market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, which can spread directly or indirectly from person to person, through contaminated surfaces, food, water, or vectors like insects. The incidence of infectious diseases is rising due to factors such as globalization, antibiotic resistance, climate change, urbanization, population growth, habitat destruction, and insufficient healthcare access. CRISPR-based diagnostics enhance the fight against infectious diseases by delivering rapid and accurate pathogen detection, facilitating early diagnosis, timely intervention, and effective containment measures. For instance, in August 2024, according to the data published by the UK Health Security Agency, a UK-based executive agency, in England, the UK Health Security Agency (UKHSA) reported 368 measles cases in 2023, marking a nearly sevenfold increase from the 53 cases reported in 2022, with the West Midlands and London accounting for 44% and 33% of the cases, respectively. Therefore, the rising incidence of infectious diseases is driving the CRISPR-based diagnostics industry.

Key Players In The Global CRISPR-Based Diagnostics Market

Major companies operating in the crispr-based diagnostics market are Thermo Fisher Scientific Inc., Integrated DNA Technologies Inc., Molbio Diagnostics, Horizon Discovery, Synthego Corporation, Caribou Biosciences, Mammoth Biosciences, Epic Bio, VedaBio, CrisprBits, SNIPR BIOME ApS, TOLO Biotech, Intact Genomics, Agdia Inc., ToolGen Inc., Caspr Biotech, GenScript, Twist Bioscience, Revvity Discovery Limited, Danaher Corporation, Scope Biosciences, CRISPR Diagnostics, Gene Editing Institute, Aptitude Medical Systems, Qiagen, Abingdon Health

Global CRISPR-Based Diagnostics Market Trends and Insights

Major companies operating in the CRISPR-based diagnostics market are focusing on developing strategic partnerships to enhance accessibility to rapid and accurate diagnostics through CRISPR-based point-of-care tests. A strategic partnership is a long-term collaboration between two or more organizations that share resources and expertise to achieve mutual goals and enhance their competitive advantage. For instance, in August 2023, CrisprBits Private Limited, an India-based biotechnology company, announced a strategic collaboration with Molbio Diagnostics, an India-based molecular diagnostics company, to develop CRISPR-based Point-of-Care Tests (POCTs). This collaboration focuses on creating rapid, precise, and cost-effective diagnostic tools leveraging CRISPR technology for detecting pathogens and genetic markers. These POCTs aim to enhance diagnostic accessibility in diverse settings, including resource-limited areas, while ensuring swift and accurate disease detection. The partnership combines CrisprBits' expertise in CRISPR-based platforms with Molbio's manufacturing and distribution capabilities to bring these tests to a global market.

What Are Latest Mergers And Acquisitions In The CRISPR-Based Diagnostics Market?

In February 2024, Ginkgo Bioworks Holdings Inc., a US-based biotechnology company, acquired Proof Diagnostics Inc. for an undisclosed amount. The acquisition aims to bolster Ginkgo's gene therapy services by integrating Proof Diagnostics' OMEGA RNA-programmable nuclease technology and enhancing its gene editing capabilities. This move strengthens Ginkgo's capacity to deliver advanced solutions in therapeutic development and precision gene editing. Proof Diagnostics Inc. is a US-based company that provides cutting-edge CRISPR-based COVID-19 molecular testing solutions.

Regional Outlook

North America was the largest region in the CRISPR-based diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the CRISPR-Based Diagnostics Market?

The CRISPR-based diagnostics market includes revenues earned by entities by providing services such as diagnostic testing services, custom CRISPR assays development, screening and surveillance services, and regulatory and compliance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The CRISPR-based diagnostics market also consists of sales of CRISPR-based RNA detection systems, CRISPR-based monitoring tools, lateral flow assays, and CRISPR-based test platforms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the CRISPR-Based Diagnostics Market Report 2026?

The crispr-based diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the crispr-based diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.